1-7 of 7
Richard R. Furman
Close
Sort by
Journal Articles

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

Clinical Trials & Observations
Javid J. Moslehi, Richard R. Furman, Constantine S. Tam, Joe-Elie Salem, Christopher R. Flowers, Aileen Cohen, Meng Zhang, Jun Zhang, Lipeng Chen, Han Ma, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2478–2490.
https://doi.org/10.1182/bloodadvances.2023011641
Published: 2024
Includes: Supplemental data
Journal Articles

Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis

Clinical Trials & Observations
Geffen Kleinstern, Nicholas J. Boddicker, Daniel R. O’Brien, Cristine Allmer, Kari G. Rabe, Aaron D. Norman, Rosalie Griffin, Huihuang Yan, Tao Ma, Timothy G. Call, Laura Bruins, Sochilt Brown, Cecilia Bonolo de Campos, Curtis A. Hanson, Jose F. Leis, Wei Ding, Celine M. Vachon, Neil E. Kay, Christopher C. Oakes, Alexander S. Parker, Danielle M. Brander, J. Brice Weinberg, Richard R. Furman, Tait D. Shanafelt, James R. Cerhan, Sameer A. Parikh, Esteban Braggio, Susan L. Slager
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2118–2129.
https://doi.org/10.1182/bloodadvances.2023012242
Published: 2024
Includes: Supplemental data
Journal Articles

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

Clinical Trials & Observations
Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J. Schuster, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, John P. Leonard, Peter Martin, Jia Ruan
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6579–6588.
https://doi.org/10.1182/bloodadvances.2023010606
Published: 2023
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data
Journal Articles

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Clinical Trials & Observations
Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1553–1562.
https://doi.org/10.1182/bloodadvances.2018030007
Published: 2019
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data
Journal Articles

Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment

Sara Serra, Tiziana Vaisitti, Valentina Audrito, Cinzia Bologna, Roberta Buonincontri, Shih-Shih Chen, Francesca Arruga, Davide Brusa, Marta Coscia, Ozren Jaksic, Giorgio Inghirami, Davide Rossi, Richard R. Furman, Simon C. Robson, Gianluca Gaidano, Nicholas Chiorazzi, Silvia Deaglio
Journal: Blood Advances
Blood Adv (2016) 1 (1): 47–61.
https://doi.org/10.1182/bloodadvances.2016000984
Published: 2016
Includes: Supplemental data